Skip to main
XOMA

XOMA (XOMA) Stock Forecast & Price Target

XOMA (XOMA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

XOMA Royalty Corp is positioned for robust financial growth, with royalty-based income projected to increase revenues by over 20% annually through 2026 and beyond, driven by the commercial sales of Vabysmo and recent product launches. The company's total income surged to $28.5 million in 2024 from $4.8 million in 2023, fueled by increased receipts from purchased receivables and enhanced customer contracts. Looking forward, XOMA anticipates revenues of $49.0 million for 2026, representing a 36% increase from 2025, alongside potential contributions from earlier-stage assets and milestone payments, further solidifying its positive financial outlook.

Bears say

XOMA Royalty Corp has experienced significant revenue and net earnings variability, primarily influenced by fluctuations in the international market and external factors such as global economic downturns, tariffs, and changes in governmental reimbursement policies, all of which could adversely impact its operations. The potential for failed clinical trials or difficulties in securing funding for drug development further exacerbates the company's financial vulnerability, especially in light of the removal of a near-term revenue driver from its projections. Additionally, the departure of key executives could hinder the company's ability to maintain operational continuity and industry knowledge, further undermining investor confidence and contributing to stock volatility.

XOMA (XOMA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About XOMA (XOMA) Forecast

Analysts have given XOMA (XOMA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, XOMA (XOMA) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $63.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $63.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

XOMA (XOMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.